Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 141 participants.
Also called NCT02577016
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 141 participants
- Sponsor
- Registry
-
NCT02577016
-
- Other papers using this trial's data
- A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT02577016. Randomized; double masking; primary purpose treatment. Start 2015-11-05 (actual); primary completion 2016-11-18 (actual). Results posted on 2018-03-07.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Ipragliflozin
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct02577016- Content hash
96c9a171906815027fdc7f9074c63af2f9c19bf09494885b74155963eeb2bfec